Alexion Pharma (ALXN) Tops Q1 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Alexion Reports First Quarter 2021 Results
April 30, 2021 8:00 AM EDT1Q21 total revenues of $1,636.5 million, a 13% increase over 1Q20 1Q21 GAAP diluted EPS of $2.86; non-GAAP diluted EPS of $3.52 Completed enrollment in Phase 3 studies of ULTOMIRIS® (ravulizumab) in NMOSD and ALS Filed for regulatory approval of ONDEXXYA® [coagulation factor Xa (recombinant), inactivated-zhzo] in Japan Secured UK reimbursement for ULTOMIRIS in PNH and ONDEXXYA for GI bleeds Received U.S. Federal Trade Commission clearance for proposed acquisition by AstraZeneca; transaction expected to close in... More
